Amylin receptor agonists: a novel pharmacological approach in the management of insulin-treated diabetes mellitus

Author： Nyholm Birgit   Brock Birgitte   Ørskov Lotte   Schmitz Ole  

Publisher： Informa Healthcare

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.10, Iss.9, 2001-09, pp. : 1641-1652

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Optimising Therapy for Insulin-Treated Type 2 Diabetes Mellitus

By Hermann L.  

Drugs & Aging, Vol. 17, Iss. 4, 2000-10 ,pp. : 283-294

Adis International

Access to resources Recommend Favorite

Amylin Replacement With Pramlintide as an Adjunct to Insulin Therapy in Type 1 and Type 2 Diabetes Mellitus: A Physiological Approach Toward Improved Metabolic Control

By  

Current Pharmaceutical Design, Vol. 7, Iss. 14, 2001-09 ,pp. : 1353-1373

Bentham Science Publishers

Access to resources Recommend Favorite

Peroxisome Proliferator-Activated Receptor-γ Agonists for Management and Prevention of Vascular Disease in Patients with and without Diabetes Mellitus

By Ríos-Vázquez Ramón   Marzoa-Rivas Raquel   Gil-Ortega Ignacio   Juan Carlos Kaski  

American Journal of Cardiovascular Drugs, Vol. 6, Iss. 4, 2006-01 ,pp. : 231-242

Adis International

Access to resources Recommend Favorite

Novel GLP-1 receptor agonists for diabetes

By Garber Alan J  

Expert Opinion on Investigational Drugs, Vol. 21, Iss. 1, 2012-01 ,pp. : 45-57

Informa Healthcare

Access to resources Recommend Favorite

Insulin receptor substrate polymorphisms and Type 2 diabetes mellitus

By Sesti Giorgio  

Pharmacogenomics, Vol. 1, Iss. 3, 2000-08 ,pp. : 343-357

Future Medicine

Access to resources Recommend Favorite